Idiopathic hypersomnia (IH) is a chronic, debilitating sleep disorder mainly characterized by excessive daytime sleepiness (EDS) as well as prolonged nocturnal sleep and/or daytime naps, unrefreshing sleep, sleep inertia, and autonomic dysfunction. These symptoms, in turn, often result in diminished psychosocial functioning, cognitive dysfunction, school/work performance, and quality of life (QoL), subsequently impacting family, friends, and work colleagues, as well as public health and safety. Contributing to the debilitation caused by IH is the failure of health care practitioners (HCPs) to accurately diagnose IH in a timely manner. In fact, an accurate diagnosis can often take years, leaving patients with IH struggling with personal, work, and psychosocial dysfunction in the interim.
While advances in sleep medicine have resulted in the first and only FDA-approved therapy for IH, incorporating this therapy into practice and monitoring treatment efficacy requires best practices. Please join Dr. Foldvary-Schaefer in this adaptive learning activity for a personalized journey through the latest clinical evidence for IH, strategies to transition patients to new therapies, and evidence-based tools to assess symptom severity and treatment effectiveness.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care providers, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Foldvary-Schaefer reports the following financial relationships: Advisory Board: Jazz Pharmaceuticals, Inc. (Publication Committee). Research Support: Jazz Pharmaceuticals, Inc.; Suven Pharmaceuticals Limited; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals
The following Peer Reviewer and CME Outfitters staff reports no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at (877) CME-PROS or (877) 263-7767.
AL-004-011823-43
